On November 6, 2025, Novo Nordisk and Eli Lilly joined federal officials at the White House to present their response to the July 2025 Most-Favored-Nations (MFN) Executive Order. Their plan outlines new pricing strategies for GLP-1 medications used to treat diabetes and support weight loss across Medicare, Medicaid and direct-to-consumer (DTC) channels. Through the Medicaid GENEROUS program and Medicare Part D, current injectable GLP-1 doses for diabetes and weight loss will be offered to payers at $245/month. For Medicare Part D patients, weight loss GLP-1 medications will be offered with a $50 copay.

These announcements will also bring pricing updates for GLP-1 medications for diabetes and weight loss on TrumpRx, a DTC platform. The timing of these price changes has not been announced. While TrumpRx is expected to launch in January 2026, Eli Lilly leadership has shared that they anticipate pricing as early as April 2026. The long-term goal is to align TrumpRx pricing with Medicare and Medicaid at $245/month over the next two years.

Until the full rollout, here’s what we know about transitional pricing:

  • Ozempic (diabetes) and Wegovy (weight loss) will be offered at $350/month, down from $499/month with their current co-pay card and NovoCare program.
  • Mounjaro (diabetes) will not be listed on TrumpRx per this announcement.

 

Pricing Projections for GLP-1s Awaiting FDA Approval

The announcement also provided pricing projections for GLP-1 medications still awaiting FDA approval, including oral agents for weight loss and a formulation of Zepbound not yet FDA approved. It was shared that these medications would receive a shortened FDA approval time of 1-2 months, compared to the standard 10-12 months, once they are ready for review.

  • Zepbound (weight loss) multi-dose pens, if approved, will be offered at $299-$449/month, down from $349-$499/month for the current vials and single-dose pens through copay cards and LillyDirect.
  • Oral Wegovy (weight loss), if approved, will start at $150/month for the lowest dose; no comment on the higher doses.
  • Oral Orforglipron (weight loss), if approved, will be offered at $149-$399/month.

 

Potential Impacts for Commercial Insurance Programs

During the White House announcement, the Deputy Administrator of CMS shared that the companies agreed to MFN pricing for commercial insurance as well. However, Eli Lilly leadership followed up with a press release stating that the scope of their agreement does not extend to commercial insurance.

 

Conclusion

What does all of this mean for plan sponsors? While their members can access DTC options like TrumpRx, plan sponsors currently have no way to access these prices for the prescriptions paid through their insurance plans. It is anticipated that new solutions and potentially new vendors will come to market in 2026, allowing members to access these lower prices through insurance or cash payments, with amounts still counting toward deductibles and out-of-pocket limits. While lower upfront prices are a move in the right direction, especially given the heavy spending on pharmacy benefits today, they could lead to increased complexity, additional middlemen and lost savings opportunities for employers.